Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer

Kyoko Inadomi, Hitoshi Kusaba, Yuzo Matsushita, Risa Tanaka, Kenji Mitsugi, Kohei Arimizu, Gen Hirano, Akitaka Makiyama, Hirofumi Ohmura, Keita Uchino, Fumiyasu Hanamura, Yoshihiro Shibata, Miyuki Kuwayama, Taito Esaki, Kotoe Takayoshi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Significant efficacy of oxaliplatinbased chemotherapy has been demonstrated for advanced gastric cancer (AGC). However, the appropriate dose of oxaliplatin, and the efficacy and toxicity of administration of oxaliplatin subsequent to cisplatin therapy still remain unclear. Patients and Methods: In total, 55 patients with AGC that were scheduled to receive oxaliplatin-based chemotherapy were prospectively examined. Results: The median age was 67 years and oxaliplatin was administered to 39 (71%) patients as first-line and in 16 (29%) patients as second-line therapy. An initial dose of 130 or 100 mg/m2 of oxaliplatin was administered to 11 and 36 patients, respectively. The overall response rates (ORR) and median progression free survival (mPFS) were 86 and 33%, and 7.2 and 7.8 months, respectively. Compared to 100 mg/m2, the relative dose intensity was significantly lower and severe toxicity tended to increase with oxaliplatin at 130 mg/m2. A total of 10 patients (18%) had a prior cisplatin-based therapy. The ORR of the patients pretreated with cisplatin was 14% and the mPFS was 6.1 months. Conclusion: An initial oxaliplatin dose of 130 mg/m2 resulted in a good response, but tended to increase the risk of toxicity. Subsequent oxaliplatin-based therapy after cisplatin exhibited modest efficacy, especially in cases with cisplatin intolerance.

Original languageEnglish
Pages (from-to)2663-2671
Number of pages9
JournalAnticancer research
Volume37
Issue number5
DOIs
Publication statusPublished - May 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer'. Together they form a unique fingerprint.

  • Cite this

    Inadomi, K., Kusaba, H., Matsushita, Y., Tanaka, R., Mitsugi, K., Arimizu, K., Hirano, G., Makiyama, A., Ohmura, H., Uchino, K., Hanamura, F., Shibata, Y., Kuwayama, M., Esaki, T., Takayoshi, K., Arita, S., Ariyama, H., Akashi, K., & Baba, E. (2017). Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer. Anticancer research, 37(5), 2663-2671. https://doi.org/10.21873/anticanres.11614